Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 29352500 | HLA-DR (HLA-DR) | ebv infections | NA | NA | NA | positive | |
| these nk and gd t cells strongly expressed the activation marker human leukocyte antigen-dr and were considered to be cellular targets of ebv infections. | |||||||
| 8160928 | HLA-DR (HLA-DR) | neurofibromas | NA | NA | NA | positive | |
| such factor-xiiia-positive cells in cutaneous neurofibromas, however, differ from conventional fibroblasts in the strong expression of hla-dr antigen and lack of prolyl 4-hydroxylase. | |||||||
| 8160928 | HLA-DR (HLA-DR) | neurofibromas | NA | NA | NA | positive | |
| the results suggest that fibroblastlike cells in cutaneous neurofibromas are probably derived from factor-xiiia- and hla-dr antigen-positive connective tissue cells in peripheral nerves. | |||||||
| 8820079 | HLA (HLA) | heart failure | NA | prednisone | NA | unclassified | |
| pretransplant status, etiology of heart failure, ischemic time, degree of hla disparity, cumulative corticosteroid exposure, and number of rejection episodes failed to correlate with any exercise parameter. | |||||||
| 11872239 | HLA (HLA) | heart failure | NA | calcium | NA | positive | |
| lvad recipients demonstrated higher frequencies of anti-hla antibodies and serum levels of soluble cd40 ligand compared with heart failure controls. | |||||||
| 12431496 | HLA (HLA) | heart failure | NA | NA | NA | positive+negation | |
| within this small study group, gender, age, etiology of heart failure, previous cardiac surgery and duration of vad support showed no statistically significant correlation with formation of hla antibodies. | |||||||
| 16766065 | HLA-DR (HLA-DR) | heart failure | NA | NA | NA | positive | |
| in chronic heart failure tnfalpha generation capacity increases while hla-dr expression decreases compared to controls. | |||||||
| 22168269 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | heart failure | NA | NA | NA | unclassified | |
| donor age, recipient age, recipient gender, etiology of heart failure, ischemic time, human leukocyte antigen matching, cytomegalovirus, lipid profile, and rejection episodes were the most studied factors. | |||||||
| 23782659 | HLA-A10 (BROAD ANTIGEN) | heart failure | NA | NA | NA | positive | |
| the patient, with end-stage heart failure, was positive only for antibodies of hla class i (anti-a2, a10, b17), and luminex platform (one lambda kit) showed a panel-reactive antibody score of 64%. | |||||||
| 23782659 | HLA-B17 (BROAD ANTIGEN) | heart failure | NA | NA | NA | positive | |
| the patient, with end-stage heart failure, was positive only for antibodies of hla class i (anti-a2, a10, b17), and luminex platform (one lambda kit) showed a panel-reactive antibody score of 64%. | |||||||
Copyright 2024